We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Plasma Neurofilament Light Validated Biomarker for Neurological Conditions

By LabMedica International staff writers
Posted on 30 Jun 2021
Print article
Image: The Simoa HD-X analyzer is used with the Simoa NF-light assay is a digital immunoassay for the quantitative determination of NfL in serum, plasma and CSF (Photo courtesy of Quanterix)
Image: The Simoa HD-X analyzer is used with the Simoa NF-light assay is a digital immunoassay for the quantitative determination of NfL in serum, plasma and CSF (Photo courtesy of Quanterix)
In the management of neurological disorders, reliable and easily accessible biomarkers are needed to recognize or rule out an underlying neurodegenerative process contributing to cognitive decline at the earliest stage.

Axonal degeneration or injury is a predominant feature of many neurodegenerative disorders that results in irreversible impairment. In response to such damage, neurofilament light chain (NfL), a structural component of the neural cytoskeleton, is released into the extracellular space initiating a concentration increase in the cerebrospinal fluid (CSF).

Clinical Medical Scientists at the University of Gothenburg (Mölndal, Sweden) and their colleagues measured NfL levels in plasma from 2,269 individuals from two independent, multicenter cohorts. The subjects included patients with 13 neurodegenerative disorders, Down syndrome, and depression, as well as cognitively unimpaired controls.

Individuals clinically classified as cognitively unimpaired (CU), subjective cognitive decline (SCD) (Lund cohort only), and mild cognitive impairment (MCI) were further categorized into amyloid-beta (Aβ)-negative (Aβ−) or Aβ-positive (Aβ+). In the Lund cohort, Aβ-positivity was classified by CSF with Aβ42/Aβ40 < 0.091 by EUROIMMUN immunoassays (EUROIMMUN AG, Lübeck, Germany). Plasma NfL concentration was measured using two highly correlated versions of a single-molecule array method (Simoa; Quanterix; Billerica, MA, USA).

The scientists reported that plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical Parkinsonian disorders. They demonstrated that plasma NfL is clinically useful in identifying atypical Parkinsonian disorders in patients with Parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment.

Nicholas Ashton, PhD an assistant professor and a senior author of the study, said, “If you present with a Parkinson's syndrome, NfL is extremely useful in determining whether you have Parkinson's with dementia or pure Parkinson's disease. It is a test a clinician can request if they want it, and so we are doing this routinely. It has proven to be useful to physicians in their clinical workups.”

The authors concluded that plasma NfL concentrations are increased across multiple neurodegenerative disorders but are highest in samples from individuals with ALS, frontotemporal dementia (FTD), and Down syndrome Alzheimer’s disease (DSAD). Though plasma NfL cannot differentiate between different cognitive impairment disorders, in patients with parkinsonism, high plasma NfL values indicate atypical parkinsonian disorders and in patients with Down syndrome (DS), high plasma NfL differentiates between those with and without dementia, suggesting it may be useful in both clinical settings in these patients. The study was published on June 7, 2021 in the journal Nature Communications.

Related Links:
University of Gothenburg
EUROIMMUN AG
Quanterix


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.